Ruxolitinib Response in Teens, Adults With Vitiligo Compared Ruxolitinib Response in Teens, Adults With Vitiligo Compared

Pooled data from the phase 3 TRuE-V1 and TRuE-V2 studies were used to evaluate responses in a subset of adolescents treated with the topical JAK inhibitor for vitiligo.Medscape Medical News

Source: Medscape Dermatology Headlines - July 25, 2023 Category: Dermatology Tags: Dermatology News Source Type: news